Although in our setting isCGM is universally available to individuals with T2D on multiple daily insulin injections, and the lack of device use is most commonly due to personal preference, we did not include a matched control group of individuals without isCGM. The gene discussed is INS; the disease is type 2 diabetes mellitus.